Laboratory results with the NPRL2 tumor suppressor gene demonstrated that infusions of NPRL2 nanoparticles in combination with cisplatin resulted in a 90 percent inhibition of tumor growth in human lung cancer cells compared to control treatments, reported Introgen Therapeutics, Inc. (Nasdaq: INGN – News).
Bacteria that can cause deadly infections in humans and animals have shown promise in treating cancer by ?eating? tumors from the inside out. Now, two new studies at the Johns Hopkins Kimmel Cancer Center have demonstrated that, combined with specially-packaged anti-cancer drugs, the bacterial therapy?s prospects for cancer eradication have dramatically improved.
To find a cure for cancer, the modern-day plague of our society — is synonymous to finding the holy grail of science. At a recent EuroDYNA conference in Brno, Czech Republic, scientists from around Europe came together to share their research carried out in the field of genetics and cell nucleus architecture. A greater understanding of the body’s building blocks might ultimately lead to a better understanding of human disease.
Children’s Hospital Oakland Research Institute in California publishes new research that identifies a specific human enzyme that could kill cancer cells.
The following are based on abstracts presented at the American Association for Cancer Research?s Fifth Annual International Conference on Frontiers in Cancer Prevention Research held November 12 ? 15 in Boston.
The news that the world’s first targeted therapy, trastuzumab (Herceptin), is now available for many women with early-stage HER2-positive breast cancer “highlights a truly significant advance in the management of breast cancer,” says Edith Perez, M.D., director of Mayo Clinic’s Breast Clinic in Jacksonville, Fla.
Passive smoking does cause respiratory troubles in healthy adults, a new study confirms. The study is in the November issue of the American Journal of Respiratory and Critical Care Medicine.
The U. S. Food and Drug Administration (FDA) today expanded the approved use of Herceptin, a biological cancer drug. The new indication is for Herceptin, in combination with other cancer drugs, for the treatment of HER2 positive breast cancer after surgery (lumpectomy or mastectomy). FDA granted priority review to the supplemental application for Herceptin.
A new use for the breast cancer drug Herceptin was approved by the FDA yesterday, a move that means more treatment options for the 25 percent of breast cancer patients with early-stage HER-2 positive breast cancer.
Despite the many advances that have been made over the past 30 years in the prevention, detection, and treatment of cancer, one grim fact remains: the overall five-year lung cancer survival rate is only 15%. The Abramson Cancer Center of the University of Pennsylvania has joined an international effort launched by Roswell Park Cancer Institute to potentially revolutionize the prevention and management of this disease.